Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Streptococcal pyrogenic exotoxin B (SpeB), also known as streptococcal cysteine protease, is a secreted enzyme produced by Streptococcus pyogenes. It is a member of the papain-like family of cysteine proteases and is a major virulence factor implicated in invasive diseases such as necrotizing fasciitis. SpeB is synthesized as an inactive zymogen that is converted to its active protease form by autolytic cleavage. It cleaves a broad spectrum of host and bacterial proteins, facilitating tissue invasion, immune evasion, and pathology. Structurally, SpeB is a distant homolog of papain and cathepsins, but it forms a unique class among prokaryotic proteases. Its notable features include a non-canonical catalytic triad and the presence of an integrin-binding RGD motif, which may further contribute to its pathogenesis[1][2][8][9].
Inhibition of protease active site (cysteine protease inhibitors binding to catalytic cysteine)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcal pyrogenic exotoxin B (SpeB).